Sphingosine 1-phosphate receptor subtype 1 (S1P

Alzheimer's disease Brain Human Mapping Rodents S1P(1) receptor [(35)S]GTPγS

Journal

Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169

Informations de publication

Date de publication:
22 Oct 2024
Historique:
received: 15 07 2024
revised: 10 10 2024
accepted: 21 10 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 24 10 2024
Statut: aheadofprint

Résumé

Some specific lipid molecules in the brain act as signaling molecules, neurotransmitters, or neuromodulators, by binding to specific G protein-coupled receptors (GPCR) for neurolipids. One such receptor, sphingosine 1-phosphate receptor subtype 1 (S1P

Identifiants

DOI: 10.1016/j.nbd.2024.106713 PMID: 39448041
pubmed: 39448041
pii: S0969-9961(24)00315-2
doi: 10.1016/j.nbd.2024.106713
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106713

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jonatan Martínez-Gardeazabal (J)

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), B° Sarriena s/n, 48940 Leioa, Spain; Neurodegenerative Diseases, BioBizkaia Health Research Institute, Bizkaia, Spain, 48903 Barakaldo, Spain.

Gorka Pereira-Castelo (G)

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), B° Sarriena s/n, 48940 Leioa, Spain.

Marta Moreno-Rodríguez (M)

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), B° Sarriena s/n, 48940 Leioa, Spain.

Alberto Llorente-Ovejero (A)

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), B° Sarriena s/n, 48940 Leioa, Spain.

Manuel Fernández (M)

Neurodegenerative Diseases, BioBizkaia Health Research Institute, Bizkaia, Spain, 48903 Barakaldo, Spain; Department of Neurology, Hospital Universitario de Cruces, 48903 Barakaldo, Spain.

Iván Fernández-Vega (I)

Department of Pathology, Hospital Universitario Central de Asturias, Avda. Roma, s/n, 33011 Oviedo, Spain; Health Research Institute of Principality of Asturias (ISPA), Av. del Hospital Universitario, s/n, 33011 Oviedo, Spain.

Iván Manuel (I)

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), B° Sarriena s/n, 48940 Leioa, Spain; Neurodegenerative Diseases, BioBizkaia Health Research Institute, Bizkaia, Spain, 48903 Barakaldo, Spain. Electronic address: ivan.manuel@ehu.eus.

Rafael Rodríguez-Puertas (R)

Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), B° Sarriena s/n, 48940 Leioa, Spain; Neurodegenerative Diseases, BioBizkaia Health Research Institute, Bizkaia, Spain, 48903 Barakaldo, Spain.

Classifications MeSH